Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 34.99M |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.11% | -1.68% | +43.40% | +95.58% | 66.93B | |
| +1.01% | -0.78% | +35.20% | +75.75% | 61.97B | |
| -2.68% | +1.31% | -11.61% | +374.39% | 28.26B | |
| +4.55% | +1.36% | +26.52% | +17.28% | 24.59B | |
| +1.59% | -0.28% | +0.51% | -13.56% | 24.3B | |
| +1.03% | -1.59% | +18.44% | -22.25% | 19.41B | |
| -3.03% | -2.29% | +181.72% | +333.47% | 16.77B | |
| +3.44% | -1.88% | -5.46% | +547.21% | 14.18B | |
| +4.39% | +5.90% | -3.38% | +858.12% | 14B | |
| Average | +0.88% | -2.95% | +31.70% | +251.78% | 30.05B | |
| Weighted average by Cap. | +0.27% | -2.83% | +32.19% | +172.70% |
